San Francisco, 6
November 2018: The global urothelialcancer drugs market size
is expected to reach USD 3.6 billion by 2023, as per a new report by Grand View
Research, Inc., exhibiting a 22.9% CAGR during the forecast period.
Availability of novel drugs, presence of a strong pipeline, rising disease
incidence, unhealthy lifestyle, and increasing awareness are driving this
market.
Urothelial cancer is the ninth most common
malignancy in the world, with approximately 2.5 million patients and 420,000
newly diagnosed cases each year. Approximately 59% of bladder cancer cases
occur in developed regions such as North America and Europe. The disease has
the highest lifetime cost of care per patient among all tumors in U.S. due to
its high relapse rate and invasive lifelong monitoring including cystoscopy
follow-ups.
Bladder transitional cell carcinoma (TCC)
is the most common histology, accounting for nearly 90% of all urinary cancer
cases. Urothelial cancer is clinically divided into three categories:
non-muscle invasive bladder cancer (NMIBC, early stage), muscle invasive
disease (MIBC, mid stage), and metastatic disease (late stage). At diagnosis,
approximately 70% of cases are non-muscle invasive disease, 20% are at the
muscle invasive stage, and 10% are at the advanced stage.
Access Research Report
of Urothelial Cancer Drugs Market @ www.grandviewresearch.com/industry-analysis/urothelial-cancer-drugs-market
Further key findings from the report suggest:
· The U.S. dominated the urothelial cancer
market, with more than 60% of the market in 2017. Several factors such as presence
of a large target population, increased adoption of novel therapeutics, and
multiple product launches will drive the market in this region
· The therapeutic landscape is expected to
witness a paradigm shift toward combination therapies and novel immuno-oncology
products. Combination regimens, particularly checkpoint inhibitors, are likely
to be introduced in the first-line setting. Immune checkpoint blockade therapy
is expected to replace the current standard of care in bladder cancer in the
foreseeable future
· Therapeutic development in second-line
setting for chemotherapy-intolerant patients is expected to have a major impact
in the urothelial cancer space
· Urothelial cancer presents a strong
opportunity for introducing first-in-class treatments due to high unmet needs.
Opportunities remain in the non-muscle invasive bladder cancer (NMIBC) setting
where there exists an unmet need for treatment options for patients who are
BCG-intolerant or ineligible
· Some of the key players operating in this
market are Roche, Merck, Bristol-Myers Squibb, AstraZeneca, and Pfizer.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global urothelial cancer drugs market based on treatment class and country:
Urothelial Cancer Drugs Treatment Class
Outlook (USD Million, 2017 - 2023)
·
Chemotherapy
·
Immunotherapy
Urothelial Cancer Drugs Country Outlook
(USD Million, 2017 - 2023)
·
U.S.
·
U.K.
·
France
·
Germany
·
Italy
·
Spain
·
Japan
Access Press Release of
Urothelial Cancer Drugs Market@ www.grandviewresearch.com/press-release/global-urothelial-cancer-drugs-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
